SB-267268 inhibits the attachment of bothαvβ3-transfected HEK293 cells to microtiter plate wells precoated with arginine-glycine-aspartic acid (RGD)-containing matrix proteins (IC50: 12 nM). SB-267268 also inhibits vitronectin-mediated human and rat aortic smooth-muscle-cell (SMC) migration (IC50: approximately 12.3 nM and 3.6 nM, respectively) [1].

SB-267268 (60 mg/kg; bi-daily, i.p.) decreases blood vessel profiles (BVPs) in the inner retina by 50%. VEGF and VEGFR-2 gene expression in the inner nuclear layer (INL) and the ganglion cell layer (GCL) is reduced in ROP mice treated with SB-267268 [1].